Drug Profile
SEL 212
Alternative Names: Non-immunogenic uricase; Pegadricase-SVP; Pegsiticase-SVP; SEL-037/SEL-110; SEL-212; SEL-212A; SEL-212B; SVP-Rapamycin/pegsiticaseLatest Information Update: 05 Dec 2023
Price :
$50
*
At a glance
- Originator Selecta Biosciences
- Developer Cartesian Therapeutics
- Class Antigouts; Enzymes; Oxidoreductases; Polyethylene glycols; Recombinant proteins
- Mechanism of Action Urate oxidase replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Gout
Most Recent Events
- 10 Nov 2023 Pooled analysis of adverse events and efficacy data from a phase III DISSOLVE trials in Gout presented at the ACR convergence 2023 (ACR-2023)
- 31 Oct 2023 Selecta Biosciences and Swedish Orphan Biovitrum enter into development and marketing agreement for ImmTOR for SEL 212
- 17 Aug 2023 Selecta BioSciences announces intention to submit Biologics license application (BLA) to the US FDA for Gout in the first half of 2024